Aprepitant Kit
Product Images NDC 68462-112

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aprepitant (NDC 68462-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

125mg 6caps

Packaging label for Aprepitant Capsules USP 125 mg by Glenmark Pharmaceuticals Inc., USA. The label indicates the product is prescription only, contains 6 capsules, and includes storage instructions and manufacturer details. The label features the NDC 68462-585-76 and the Glenmark logo in red.*

FDA Label Image

125mg 80mg 3cap

Label for Aprepitant Capsules USP, available in 125 mg and 80 mg strengths, oral capsule form. The packaging indicates a 3-day pack containing 3 capsules. Manufactured for Glenmark Pharmaceuticals Inc., USA. The label includes storage instructions, capsule images with imprint codes, and contact details.*

FDA Label Image

40mg 1caps

Aprepitant Capsules USP 40 mg oral capsule packaging label by Glenmark Pharmaceuticals Inc. The label includes the proprietary and generic name, strength (40 mg), manufacturer details, storage instructions, barcode, and note that the package contains 1 capsule. It also states 'Rx Only' and identifies the product as a human prescription drug.*

FDA Label Image

80mg 6cap

Flat packaging label for Aprepitant Capsules USP 80 mg by Glenmark Pharmaceuticals Inc., USA. The label shows the NDC number 68462-584-76, the dosage form as capsules, and a quantity of 6 capsules. The design features blue borders and the Glenmark logo in red. Additional text includes storage instructions, product origin (India), and contact information.*

FDA Label Image

Figure1 (Figure1)

A two-panel line graph comparing the percentage of patients over time (hours) for two studies. Both panels show patient survival curves for an Aprepitant regimen versus standard therapy, with the x-axis representing hours up to 120 and the y-axis percent of patients from 0 to 100. The Aprepitant regimen is represented by a solid line and standard therapy by a dotted line in each study.*

FDA Label Image

Figure2 (Figure2)

Bar charts displaying the percentage of patients across chemotherapy cycles in two studies comparing Aprepitant regimen versus standard therapy. The vertical axis shows percent of patients, and the horizontal axis shows chemotherapy cycles from 2 to 6. Data for patient counts per regimen are listed below the charts for each cycle in both studies.*

FDA Label Image

Figure3 (Figure3)

A line graph comparing the percent of patients over a 48-hour period for Aprepitant 40 mg and Ondansetron. The x-axis represents hours from 0 to 48, and the y-axis shows the percent of patients from 0 to 100. Two lines display patient data: one solid line for Aprepitant 40 mg (N=292) and one dotted line for Ondansetron (N=279).*

FDA Label Image

Glenmark Logo

FDA Label Image

Logo

FDA Label Image

Structure

Chemical structure diagram of the active ingredient aprepitant, showing its molecular arrangement with labeled functional groups including trifluoromethyl and fluoro substituents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.